Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the...

Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today...

Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant DOYLESTOWN, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced the...

Neuropathix, Inc. Appoints World-Renowned Pain Management Clinician Dr. Daniel Richman to the Company’s Scientific Advisory Board DOYLESTOWN, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. ("Neuropathix" or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today...